Lakefront Biotherapeutics NV Stock
Stocks
LKFT
BE0003818359
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Amsterdam
23:55:00 02/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 25.66 EUR | -0.23% |
|
-1.23% | -8.36% |
| Market Cap | 1.67B 1.88B 1.55B 1.42B 2.68B 181B 2.7B 18.86B 7.3B 91.52B 7.05B 6.9B 296B | P/E 2026 * |
-13.6x | P/E 2027 * | -5.51x |
|---|---|---|---|---|---|
| Enterprise Value | -763M -859M -712M -649M -1.22B -82.67B -1.23B -8.63B -3.34B -41.88B -3.23B -3.16B -135B | EV / Sales 2026 * |
-6.51x | EV / Sales 2027 * | 3.7x |
| Free-Float |
74.64% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Amsterdam
| LKFT | Real-time | |
CBOE
| LKFT | Real-time | |
|
Xetra
| GXE | Delayed | |
|
Xetra
| GXE | End-of-day quote | |
|
Tradegate
| GXE | Real-time | |
|
OTC Markets
| GLPGF | Delayed | |
|
Deutsche Boerse AG
| GXE | Delayed | |
|
London S.E.
| 0JXZ | Delayed | |
|
CBOE
| 0JXZ | Real-time | |
|
Wiener Boerse
| LKFT | End-of-day quote | |
|
Börse Stuttgart
| GXE | Delayed | |
|
Boerse Muenchen
| GXE | Real-time | |
|
Borsa Italiana
| 4LKFT | End-of-day quote |
Last Transcript: Lakefront Biotherapeutics NV
| 09-30 | Acquisition of Own Shares | GL |
| 09-23 | Acquisition of Own Shares | GL |
| 09-16 | Acquisition of Own Shares | GL |
| 09-09 | Acquisition of Own Shares | GL |
| 09-09 | Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | GL |
| 1 day | -0.23% | ||
| 1 week | -1.23% | ||
| Current month | -2.88% | ||
| 1 month | +2.48% | ||
| 3 months | -4.61% | ||
| 6 months | +0.23% | ||
| Current year | -8.36% |
| 1 week | 25.28 |  | 26.5 |
| 1 month | 23.12 | | 28.42 |
| Current year | 22.32 | | 30.72 |
| 1 year | 22.32 | | 32.02 |
| 3 years | 20 | | 39 |
| 5 years | 20 | | 66.28 |
| 10 years | 20 | | 252.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Gosebruch
CEO | Chief Executive Officer | 53 | 12/05/2025 |
Aaron Cox
DFI | Director of Finance/CFO | 41 | 07/07/2025 |
| Chief Operating Officer | - | 01/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Linda Higgins
BRD | Director/Board Member | 63 | 22/10/2019 |
Oleg Nodelman
BRD | Director/Board Member | 49 | 07/10/2024 |
Henry Gosebruch
BRD | Director/Board Member | 53 | 12/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/1/26 | Buy | Director | 137 | 0.0002% | ||
| 28/1/26 | Buy | Director | 375 | 0.0006% | ||
| 28/1/26 | Free | General Counsel | 235,000 | 0.3566% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23% | -1.23% | -19.41% | -20.92% | 1.88B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.23% | -0.65% | +45.43% | +113.59% | 39.24B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.59% | +137.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 117M 132M 109M 99.64M 188M 12.7B 190M 1.33B 513M 6.43B 495M 485M 20.8B | 41.9M 47.17M 39.07M 35.61M 67.22M 4.54B 67.78M 474M 184M 2.3B 177M 173M 7.43B |
| Net income | -40.7M -45.82M -37.95M -34.59M -65.29M -4.41B -65.84M -460M -178M -2.23B -172M -168M -7.22B | -213M -239M -198M -181M -341M -23.04B -344M -2.41B -932M -11.67B -899M -880M -37.73B |
| Net Debt | -2.43B -2.74B -2.27B -2.07B -3.9B -263B -3.93B -27.48B -10.65B -133B -10.27B -10.05B -431B | -1.51B -1.7B -1.41B -1.29B -2.43B -164B -2.45B -17.1B -6.62B -83.01B -6.39B -6.25B -268B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | €25.66 | -0.23% | 82,824 |
| 01/10/26 | €25.72 | -2.65% | 66,214 |
| 30/09/26 | €26.42 | +1.46% | 67,881 |
| 29/09/26 | €26.04 | +0.23% | 67,785 |
| 28/09/26 | €25.98 | 0.00% | 83,484 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LKFT Stock
Select your edition
All financial news and data tailored to specific country editions
